BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin
About this episode
Dr. Jeremy Levin discusses the risks to the scientific enterprise due to public distrust and politicized institutions.
We love to hear from our listeners. Send us a message. On the Business of Biotech this week, industry veteran Dr. Jeremy Levin, Founder, Chairman, and former CEO at Ovid Therapeutics, sits down alongside the 2026 BIO Convention to talk about why public distrust and politicized institutions are putting the scientific enterprise at risk. We dig into what biotech leaders owe patients and the public, how innovation and capital can migrate out of the U.S., and what it takes to build biotech compa...
More episodes of Business Of Biotech
- Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.
- BoB@BIO: Biotech Investing And Deals With Sofinnova's Maha Radhakrishnan, M.D.
- Targeting Tau in Alzheimer's Disease With Voyager Therapeutics' Al Sandrock, M.D., Ph.D.
- Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho
- Drug Launch Success In A Changing Commercial Landscape With ACMA's William Soliman, Ph.D.
Explore listener stats, chart rankings, contacts and more on the Business Of Biotech podcast page.